Curaleaf Holdings (CURA) announced this week that it intends to launch an unsolicited take-over bid of its rival Aurora Cannabis (ACB) in what would mark one of the most consequential consolidation moves in industry history.
On August 11, Curaleaf, now one of the largest cannabis companies in the world by revenue, informed investors that it intended to make an offer to purchase all of the issued and outstanding shares in Aurora at US$4.00 per share.
“We believe this combination represents a win-win for Curaleaf and Aurora shareholders,” Boris Jordan, Chairman and Chief Executive Officer of Curaleaf, said of the offer.
Aurora, understandably, was more cautious. Within hours, Aurora responded to the announcement disputing Curaleaf’s account of their private dealings and confirming its board would form a special committee of independent directors to weigh the proposal.
A modest price tag
Curaleaf’s offer combines 0.3463 of a Curaleaf share and US$0.75 in cash for each Aurora share, together worth US$4.00 a share for the Edmonton-based medical cannabis producer, a 45% premium to Aurora’s 30-day volume-weighted average price of US$2.75.
Strip out the cash sitting on Aurora’s own balance sheet, and Curaleaf calculates the premium at 110%. Applied to the 58.9 million Aurora shares on issue as of March 31, 2026, per the company’s most recent SEC filing, that values the bid at roughly US$236m on a basic-share basis, a figure that would run higher once outstanding options and warrants are counted.
That price tag pales in comparison to some of the landmark deals of the first ‘green rush’. Aphria’s 2020 merger with Tilray was worth roughly US$3.9bn, at the time creating what was billed as the world’s largest cannabis company by revenue.
Aurora’s own 2018 purchase of MedReleaf was reported to be worth between US$2.5bn US$3.2bn, depending on the source, while Curaleaf’s 2020 acquisition of Grassroots for US$875m also dwarfs its current bid for Aurora.
It is, however, the first time a leading cannabis company has taken a ‘hostile’ approach to acquisition since Green Growth Brands’ failed 2019 hostile bid for Aphria.
At the time, this deal was worth roughly CA$2.8bn before it lapsed without meeting the minimum tender condition. After the bid collapsed, Aphria chose a friendly merger with Tilray.
It is also illustrative of the dramatic evolution of the sector in the handful of years since these deals were considered commonplace.
Curaleaf’s roughly US$236m offer values Aurora at close to 1x its CA$320.6m in fiscal 2026 revenue, converted at around CA$1.40 to the US dollar.
Aurora’s own purchase of MedReleaf in 2018 priced the target at roughly 66 times its projected revenue, with cannabis stocks at the time commonly trading at multiples touching over 100.
Writing in Business of Cannabis earlier this year, Sean McLean, CEO of PPS, argues that the cannabis sector is artificially suppressed and will likely see a structural repricing once tax and ownership constraints ease.
Others believe it is simply a sign of maturation, and the result of lessons learned the hard way from the initial cannabis rush.
“Investors are much more disciplined and cautious about deploying capital into this sector now,” Philip Campbell, Chief Executive Officer of Herbal Dispatch, told Business of Cannabis in June.
The European prize
Valuations aside, the significance of this deal lies in the pairs’ collective European estate. Over the last few years, North America’s once booming consumer market has become wildly competitive, and largely commoditised.
Europe, by contrast, has seen rapid growth in its more stringently regulated medical markets, and the latest forecast from Prohibition Partners suggests medical cannabis sales will more than double by 2028.
Aurora
Aurora, one of the earliest movers in the European cannabis market, is now one of many North American giants doubling down on the European opportunity.
In its fiscal 2026 Q3 results, published in February, Aurora reported global medical cannabis net revenue at a then-record CA$76.2m for the quarter, up 12% year-on-year, driven primarily by its positions in Germany and Poland.
This meant that income from its medical operations accounted for 81% of its revenue, and 95% of adjusted gross profit. In Q4, this rose to 91% of total revenue, bringing the total for the full year up to 90%.
Alongside its results in February, Aurora also confirmed it would effectively exit the consumer cannabis markets in Canada from Q4 FY26 onwards, with CEO Miguel Martin telling BNN Bloomberg: “Today, we announced further focus on international medical cannabis, which has much stronger margins, much stronger growth, and a real emphasis on science and genetics in regulated markets.”
That reallocation isn’t finished. Aurora is still winding down its Canadian consumer cannabis and plant propagation businesses in favour of its medical channels, having divested its 50.1% stake in propagation unit Bevo on February 17, 2026, with the rest of the exit expected next year.
In January 2026, Aurora secured EU Community Plant Variety Rights covering the exclusive commercial control over both varieties across all 27 EU member states for two proprietary strains bred at its Aurora Coast facility in Canada, a move it said would ensure ‘high-quality, differentiated varieties can consistently reach patients and consumers worldwide’
This was backed by a US$100m at-the-market equity programme explicitly earmarked for ‘increased cultivation capacity and potential M&A.’
In Germany, its business Pedanios, holds EU-GMP certified manufacturing capacity and launched localised digital platforms in Germany, the UK and Poland in February 2026.
During its Q1 2027 earnings call, Martin said Aurora holds ‘the number one market share position, supported by strong commercial execution’ in Poland, one of the fastest growing markets in the region. Similarly, in Germany, the CEO told investors that two ‘of our proprietary cultivars [are] continuing to rank in the top 5 by sales’, while Aurora is one of only three active in-country producers of medical cannabis holding a production and R&D license’.
Curaleaf
Curaleaf’s own European operations are, similarly, helping prop up the wavering margins in North America.
Its full-year 2025 revenue of US$1.27b makes it the largest pureplay cannabis company in the world by turnover. However, this headline figure masks a third consecutive year of double-digit domestic price compression, leading its management to call 2025 ‘the trough.’
Conversely, Curaleaf International posted US$172.5m in revenue for the year, up 63%, with Q4 alone up 65% year-on-year to an annualised run rate above US$200m.
This was driven by its German operations, where Curaleaf is already the largest single supplier, and the UK, where Curaleaf Clinic held the top market share by patient count during the quarter.
Beyond flower exports, Curaleaf’s CE-certified QMID inhalation device, the first of its kind in the UK, is emerging as a differentiator as France and Spain’s incoming medical frameworks favour standardised, device-led delivery.
Curaleaf’s international arm is currently dragging group EBITDA margins by 120 basis points, and the company posted a full-year net loss of US$228m, with France and Turkey, its next hoped-for contributors, not expected online until late 2026 and early 2027 respectively.
In February, it finished a US$500m private placement of senior secured notes, which its group CEO Boris Jordan called the largest bond offering the cannabis sector has completed, pointing to institutional appetite for the deal as a sign of how capital markets now view the industry.
That refinancing left Curaleaf with US$102m in cash and, by its own account, the flexibility to pursue strategic acquisitions, the same capital position now underpinning the bid for Aurora.
The combined estate
Jordan’s stated rationale for the takeover bid suggests that combining ‘Curaleaf’s global distribution platform with Aurora’s leading international medical cannabis franchise and EU-GMP cultivation and manufacturing capacity’ would unlock ‘substantial cost and revenue synergies’, set to total a minimum of US$40m a year.
The pro forma company would carry trailing 12-month revenue of US$1.5b and adjusted EBITDA of US$350m, across a footprint spanning 17 countries.
In Europe specifically, this is less about creating a new position than consolidating two existing ones. Aurora’s number-one share in Poland, its EU-GMP manufacturing under Pedanios, and the Safari Flower Company cultivation capacity in Ontario would sit alongside Curaleaf’s status as Germany’s largest single flower supplier, its UK clinic network, and its own EU-GMP facilities in Portugal, Spain and Canada. Combined, the two companies would hold either outright leadership or a top-five product position in three of the continent’s most closely watched medical cannabis markets.
Aurora’s shares rose 22% to US$3.48 on the day of the announcement, then added a further 9.61% the following session to US$3.82, still below the US$4.00 headline offer, a gap that reflects deal-completion uncertainty as much as any expectation of a sweetened bid.
However, not everyone agrees this would be a ‘win, win’ for both companies. Analysts at TD Cowen, Derek Lessard and Ryan Neal, wrote that the offer ‘does not fully capture Aurora’s long-term intrinsic value’, pointing to Aurora’s medical cannabis leadership and genetics portfolio as reasons the business is worth more than Curaleaf is offering.
Aurora’s special committee’s review is the next milestone to watch, while analysts wait for a formal bid from Curaleaf.
